Fig 1: mCALR inhibits lung cancer progression by facilitating DC infiltration in tumor tissues. (A) A tumor formation assay was performed by injecting LLC-NC and LLC-mCALR cells, n = 5 mice. (B, C) Quantification of the volume (B) and weight (C) of tumors generated in mice, ***P < 0.001. (D–F) The relative mRNA expression levels of TLR4, TNFa, and CCL19 were detected in tumors of LLC-NC and LLC-mCALR groups using real-time PCR; *P < 0.05. (G) The relative percentages of CD11c+, CD40+, CD80+, CD86+, and MHCII+ DCs in tumors were detected using flow cytometry; ns, P > 0.05, *P < 0.05. (H) The relative percentages of CD11c+CD8a+ and CD11c+CD8a- DCs in tumors were detected using flow cytometry; ns, P > 0.05, *P < 0.05. (I) The relative percentages of CD11c+CD103+, CD11c+CD207+, and CD11c+CD317+ DCs in tumors were detected using flow cytometry; ns, P > 0.05, *P < 0.05.